Strategic merger Novonesis formed from Chr. Hansen and Novozymes presents a broader biosolutions platform with combined capabilities, signaling cross-sell opportunities across food, nutrition, pharma, agricultural, and industrial customers.
Global scale With a sizeable workforce and revenue in the billion-dollar range, the unified entity offers global reach and robust execution capacity to address multinational customers seeking integrated biosolutions and end-to-end support.
Technology edge Existing tech stack including fermentation, microbial platforms, ArchiMate, Azure DevOps, and data tooling positions Novonesis to offer advanced product development, process optimization, and digital enablement services to prospects.
Industry partnerships Recent collaborations with TurtleTree Labs, Undoage, and Manufacturing Institute indicate a growth pathway through co-development, strategic alliances, and talent pipeline programs that can be leveraged for joint offerings and proof-of-concept projects.
Market leadership As a leading biosolutions player with high visibility in Vitafoods events and continuous press coverage, there is an opportunity to target high-potential customers in foodtech, probiotics, and biomanufacturing seeking innovative, scalable biology-based solutions.